Hct-BVM

Hct-BVM (Crit Line III, Hemametrics) is an optical density monitor that can detect and visually

display the continuous recording of changes in hematocrit, relative blood volume and oxygen saturation in real time during HD. It uses a transmissive photometric technique to measure the Hct on the basis of both the absorptive properties of hemoglobin and the scattering properties of red blood cells passing through the blood chamber.

 

During UF, intravascular blood volume is inversely and linearly correlated to hematocrit changes: as fluid is removed, the Hct rises. If the UF rate exceeds the vascular refill rate, hematocrit rises sharply. Intradialytic symptoms are often preceded by a rapid rise in hematocrit (fall in relative blood volume)40 or fall in central oxygen saturation.41 Timely intervention by the nurses has been shown to reduce symptoms and prevent morbidity.

 

Several small, observational studies have supported this hypothesis. They showed improved outcomes when Hct-BVM is used to guide dialysis.40,42 In contrast to these studies,  however, the multi-center, randomized, controlled CLIMB study did not demonstrate improved patient outcome when using Hct-BVM to guide dialysis.43 This study, however, should be interpreted with caution for several reasons.

 

First, the use of Hct-guided BVM was encouraged but not mandated or monitored. The study only evaluated the availability of Hct-BVM, not its implementation. Second, the annualized mortality rate in the patients treated without Hct-guided BVM was extremely low (6.4%), substantially lower than for average patients within the United States (23.7%).

 

This suggests that, as often occurs with randomized trials, the healthier patients tend to be enrolled and results cannot be generalized to the average American population. Third, all-cause mortality was reported instead of volume-related death. This study cannot be used to discount the potential benefits of using Hct-BVM, although it does emphasize the need for developing clear and effective protocols for the use of this methodology. Baseline BVA coupled with Hct-BVM changes has potential to provide quantitative intravascular volume measurements.

 

BVA

Radioisotope BVA (BVA-100, Daxor Co.) uses a single tracer dilution technique to measure plasma volume. Red cell mass is calculated utilizing the hematocrit and the plasma volume in the intravascular space. Total blood volume then, can be calculated. BVA has been used to assess volume requirements in heart failure44,45 with promising results. If used in conjunction with vector-BIA and Hct-BVM, the three combined tools may provide more objective measures of fluid status in all body compartments.

 

The Future

Vector-BIA, Hct-BVM, and BVA provide complementary volume meas- urements. At the New York University School of Medicine’s VA New York Harbor Health Care System dialysis unit, we have been developing strategies using a combination of vector-BIA (TBW), BVA (intravascular blood volume), and Hct-BVM (dynamic, intradialytic response to volume removal) to define dynamic fluid compartment volumes in adults and the elderly.

 

By using more objective, accurate methods to dynamically evaluate fluid status in the different compartments, we ultimately hope to develop an improved method to guide ultrafiltration during thrice weekly hemodialysis.

 

Dr. Pillon is assistant professor of medicine (Nephrology) at the New York University School of Medicine, Director of Dialysis at the VA New York Harbor Health Care System. Dr. Feldschuh is President and CEO of Daxor Corporation. 

 

References

  1. Lins RL, Elseviers M, Rogiers P, et al. Importance of volume factors in dialysis related hypertension. Clin Nephrol. 1997;48:29-33.
  2. Zoccali C, Benedetto FA, Mallamaci F, et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol. 2001;12:2768-2774.
  3. Parfrey PS, Harnett JD, Griffiths SM, et al. Congestive heart failure in dialysis patients. Arch Intern Med. 1988;148:1519-1525.
  4. Harnett JD, Kent GM, Barre PE, et al. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol. 1994;4:1486-1490.
  5. Fagugli RM, Pasini P, Quintaliani G, et al. Association between extracellular water, left ventricular mass and hypertension in haemodialysis patients. Nephrol Dial Transplant. 2003;18:2332-2338.
  6. Chien S, Li S, Shyy YJ. Effects of mechanical forces on signal transduction and gene expression in endothelial cells. Hypertension. 1998;31:162-169.
  7. Rawer P, Wizemann V, Schoendorf T, Schuetterle G. Efficacy of membrane filtration, influence on hemostasis, immunoglobulins and inflammation mediators during daily plasma exchanges. Int J Artif Organs. 1983;S (6 Suppl 1):97-101.
  8. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112-119.
  9. Parfrey PS, Foley RN, Harnett JD, et al. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int. 1996;49:1428-1434.
  10. D’Elia JA, Weinrauch LA, Gleason RE, et al. Application of the ambulatory 24-hour electrocardiogram in the prediction of cardiac death in dialysis patients. Arch Intern Med. 1988;148:2381-2385.
  11. Bleyer AJ, Russell GB, Satko SG. Sudden and cardiac death rates in hemodialysis patients. Kidney Int. 1999;55:1553-1559.
  12. Iseki K, Miyasato F, Tokuyama K, et al. Low diastolic blood pressure, hypoalbuminemia, and risk of death in a cohort of chronic hemodialysis patients. Kidney Int. 1997;51:1212-1217.
  13. Zager PG, Nikolic J, Brown RH, et al. “U” curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int. 1998;54:561-569.
  14. Port FK, Hulbert-Shearon TE, Wolfe RA, et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis. 1999;33:507-517.
  15. Shoji T, Tsubakihara Y, Fujii M, Imai E. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int. 2004;66:1212-1220.
  16. Guyton AC, Hall JE. Textbook of Medical Physiology. Elsevier. 10th ed, 2000.
  17. Charra B, Calemard E, Ruffet M, et al. Survival as an index of adequacy of dialysis. Kidney Int. 1992;41:1286-1291.
  18. Charra B. Control of blood pressure in long slow hemodialysis. Blood Purif. 1994;12:252-258.
  19. Chan CT, Floras JS, Miller JA, Richardson RM, Pierratos A. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int. 2002;61:2235-2239.
  20. Chan CT. Cardiovascular effects of frequent intensive hemodialysis. Semin Dial. 2004;17:99-103.
  21. Fagugli RM, Reboldi G, Quintaliani G, et al. Short daily hemodialysis: blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients. Am J Kidney Dis. 2001;38:371-376.
  22. Nesrallah G, Suri R, Moist L, et al. Volume control and blood pressure management in patients undergoing quotidian hemodialysis. Am J Kidney Dis. 2003;42:13-17.
  23. Williams AW, Chebrolu SB, Ing TS, et al. Early clinical, quality-of-life, and biochemical changes of “daily hemodialysis” (6 dialyses per week). Am J Kidney Dis. 2004;43:90-102.
  24. Walsh M, Culleton B, Tonelli M, Manns B. A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int. 2005;67:1500-1508.
  25. Ando Y, Tabei K, Shiina A, et al. Ultrasonographic evaluation of changes in the inferior vena caval configuration during hemodialysis: relationship between the amount of water removed and the diameter of the inferior vena cava. Jap J Soc Dial Ther. 1985;18:173-179.
  26. Cheriex EC, Leunissen KM, Janssen JH, et al. Echography of the inferior vena cava is a simple and reliable tool for estimation of ‘dry weight’ in haemodialysis patients. Nephrol Dial Transplant. 1989;4:563-568.
  27. MorenoFL, Hagan AD, Holmen JR, et al. Evaluation of size and dynamics of the inferior vena cava as an index of right-sided cardiac function. Am J Cardiol. 1984;53:579-585.
  28. Leunissen KM, Kouw P, Kooman JP, et al. New techniques to determine fluid status in hemodialyzed patients. Kidney Int Suppl. 1993;41:S50-S56.
  29. Natori H, Tamaki S, Kira S. Ultrasonographic evaluation of ventilatory effect on inferior vena caval configuration. Am Rev Respir Dis. 1979;120:421-427.
  30. Sakurai T, Homma S, Tabei K, Asano Y. [Hemofiltration for the treatment of patients with congestive heart failure]. Nippon Rinsho. 1993;51:1310-1316.
  31. Dastoor H, Bernieh B, Boobes Y, et al. Plasma BNP in patients on maintenance haemodialysis: a guide to management? J Hypertens. 2005;23:23-28.
  32. Khan IA, Fink J, Nass C, et al. N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am J Cardiol. 2006;97:1530-1534.
  33. Kim SW, Park SW, Lim SH, et al. Amount of left ventricular hypertrophy determines the plasma N-terminal pro-brain natriuretic peptide level in patients with hypertrophic cardiomyopathy and normal left ventricular ejection fraction. Clin Cardiol. 2006;29:155-160.
  34. Nette RW, van den Dorpel MA, Krepel HP, et al. Hypotension during hemodialysis results from an impairment of arteriolar tone and left ventricular function. Clin Nephrol. 2005;63:276-283.
  35. Zeng C, Wei T, Jin L, Wang L. Value of B-type natriuretic peptide in diagnosing left ventricular dysfunction in dialysis-dependent patients. Intern Med J. 2006;36:552-557.
  36. Piccoli A, Rossi B, Pillon L, Bucciante, G. A new method for monitoring body fluid variation by bioimpedance analysis: the RXc graph. Kidney Int. 1994;46:534-539.
  37. Piccoli A. Identification of operational clues to dry weight prescription in hemodialysis using bioimpedance vector analysis. The Italian Hemodialysis-Bioelectrical Impedance Analysis (HD-BIA) Study Group. Kidney Int. 1998;53:1036-1043.
  38. Chertow GM, Jacobs DO, Lazarus JM, et al. Phase angle predicts survival in hemodialysis patients. J Ren Nutr. 1997;7:204-207.
  39. Pillon L, Piccoli A, Lowrie EG, et al. Vector length as a proxy for the adequacy of ultrafiltration in hemodialysis. Kidney Int. 2004;66:1266-1271.
  40. Steuer RR, Leypoldt JK, Cheung AK, et al. Reducing symptoms during hemodialysis by continuously monitoring the hematocrit. Am J Kidney Dis. 1996;27:525-532.
  41. Steuer RR, Leypoldt JK, Cheung AK, et al. Hematocrit as an indicator of blood volume and a predictor of intradialytic morbid events. Asaio J. 1994;40:M691-M696.
  42. Leypoldt JK, Cheung AK, Delmez JA, et al. Relationship between volume status and blood pressure during chronic hemodialysis. Kidney Int. 2002;61:266-275.
  43. Reddan DN, Szczech LA, Hasselblad V, et al. Intradialytic blood volume monitoring
  44. in ambulatory hemodialysis patients: a randomized trial. J Am Soc Nephrol. 2005;16:2162-2169.
  45. Androne AS, Hryniewicz K, Hudaihed A, et al. Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. Am J Cardiol. 2004;93:1254-1259.
  46. Dworkin HJ, Premo M, Dees S. Comparison of red cell and whole blood volume as performed using both chromium-51-tagged red cells and iodine-125-tagged albumin and using I-131-tagged albumin and extrapolated red cell volume. Am J Med Sci. 2007;334:37-40.